Matinas BioPharma
MTNB
22 hedge funds and large institutions have $194K invested in Matinas BioPharma in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
22% more funds holding
Funds holding: 18 → 22 (+4)
19.04% less ownership
Funds ownership: 26.3% → 7.26% (-19%)
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
90% less capital invested
Capital invested by funds: $1.97M → $194K (-$1.78M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.2K |
| 2 |
Renaissance Technologies
New York
|
+$27.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$13.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.68K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$53 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$457K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$122K |
| 3 |
Squarepoint
New York
|
-$72.9K |
| 4 |
JEST
JTC Employer Solutions Trustee
St Helier,
Jersey
|
-$72K |
| 5 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$24.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$53 | +35 | New |
|
MTNB Hedge Fund Activity: Q4 2024 in Review
22 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2024, worth a combined $194K — down 90% from $1.97M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MTNB positions and 4 closed out — a net gain of 4 holders — while 1 added to existing stakes and 7 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $36.2K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $457K sold.
- 22 institutional investors held Matinas BioPharma (MTNB) as of Q4 2024, up from 18 in Q3 2024.
- Funds reported $194K of Matinas BioPharma stock for Q4 2024, down 90% quarter-over-quarter.
- 8 funds opened new Matinas BioPharma positions in Q4 2024 and 4 closed out, a net change of +4 holders.
- The largest Matinas BioPharma buyer in Q4 2024 was Susquehanna International Group, an estimated $36.2K added.
- The largest Matinas BioPharma seller in Q4 2024 was Highbridge Capital Management, an estimated $457K sold.
Based on aggregated 13F filings for Q4 2024.